跳至主要内容
临床试验/NCT03706638
NCT03706638已完成不适用

Daily vs. Intermittent Iron Therapy in Iron Deficient Pregnant Patients: A Randomized Noninferiority Trial

UConn Health2 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2018年10月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
46
试验地点
2
主要终点
Hematologic values assessed for anemia

研究概览

简要总结

This is a randomized non inferiority trial to evaluate the response to iron therapy in the standard daily vs. intermittent (three-four times a week on nonconsecutive days) groups by using hematological markers (hemoglobin, hematocrit, transferrin, hepcidin, ferritin, human soluble transferrin receptor). The secondary outcome is to evaluate gastrointestinal discomfort and adherence to therapy between two treatment groups.

详细描述

The Centers for Disease Control and Prevention estimates that as many as 8 million American women of childbearing age are iron deficient. In a typical singleton gestation, the maternal need for iron averages close to 1000 mg. Of this 300 mg is for the fetus and placenta; 500 mg for maternal hemoglobin mass expansion; and 200 mg that is normally shed through the gut, urine, and skin. The total amount of 1000 mg considerably exceeds the iron stores of most women and results in iron-deficiency anemia unless iron supplementation is given.

Correction of anemia and restitution of iron stores can be accomplished with simple iron compounds-ferrous sulfate, fumarate or gluconate. Oral iron is an effective treatment for iron deficiency anemia and is inexpensive, safe and widely available.

In the past, a standard approach to the treatment of iron deficiency anemia was oral ferrous sulfate 325 mg (65 mg elemental iron) spaced in 3 doses each day for a total daily dose of 195 mg elemental iron. However, recent absorption studies concluded that maximal absorption of iron occurs with a dose in the range of 40 to 80 mg of elemental iron daily. This study was done in non pregnant iron-deficient women. Greater doses do not result in more iron absorption and are associated with more side effects. The findings of this study have been implemented by many into various areas of medicine.

Daily oral supplementation in pregnant women has been a long-standing, cost-effective recommended intervention both in the public health and clinical fields. However, adherence to daily iron and folic acid supplementation still faces challenges. Data from national surveys from 46 countries (2003 to 2009) indicate that about 52% to 75% of mothers receive any iron tablets during pregnancy, and the duration of supplementation is usually short.

According to a study by Khalafallah, the side effects or oral iron therapy including gastrointestinal disturbances characterized by colicky pain, nausea, vomiting, diarrhea, and constipation occur in about 50% of a patient taking iron preparations, and the investigators estimate that their patients have similar complaints and intolerances.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

Treatment groups are blinded and becomes unmasked when assigning the patient to a treatment group. At this time, the patient and the investigator becomes aware of the treatment assigned.

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women who are not underweight (BMI < 18.5 kg/m2)
  • Reproductive-aged women 18-50
  • Singleton Pregnancy.
  • Patients undergoing third trimester blood work from 26-28 weeks.
  • Women who have had previously normal first-trimester blood work (hemoglobin, hematocrit, MCV) without any evidence of existing anemia.
  • Pregnant women with anemia designated with hemoglobin concentration less than 11 g/dL or hematocrit less than 33%
  • No pre-existing iron deficiency anemia or not already on iron supplementation.

排除标准

  • Women with medical problems known to affect iron metabolism or homeostasis
  • Women with existing thalassemias or anemias.
  • Women with abnormal bloodwork indicating anemia earlier in the pregnancy.
  • Women are already taking iron supplementation during the pregnancy for treatment of iron deficiency anemia.
  • Chronic illness is influencing iron absorption.
  • Underlying malabsorption disease.
  • History of bariatric surgery.
  • Severe anemia with maternal hemoglobin levels less than 6 g/dL
  • Preterm Labor, PPROM, signs of infection.

结局指标

主要结局

Hematologic values assessed for anemia

时间窗: This will be measured 4-6 weeks after starting treatment.

Hematologic values of hemoglobin, hematocrit, transferrin, hepcidin, human soluble transferrin receptor and ferritin.

次要结局

  • Scores on self report survey of gastrointestinal adverse side effects after oral iron supplementation(Side effects will be reviewed every 2 weeks for a period of 4-6 weeks.)

研究者

发起方
UConn Health
申办方类型
Other
责任方
Principal Investigator
主要研究者

Winston Campbell

Professor, Obstetrics and Gynecology; Maternal Fetal Medicine Fellowship Program Director

UConn Health

研究点 (2)

Loading locations...

相似试验